Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia*

Cao, Bin; Gao, Hainv; Zhou, Boping; Deng, Xilong; Hu, Chengping; Deng, Chaosheng; Lu, Hongzhou; Li, Yuping; Gan, Jing; Liu, Jingyuan; Li, Hui; Zhang, Yao; Yang, Yida; Fang, Qiang; Shen, Yinzhong; Gu, Qin; Zhou, Xianmei; Zhao, Wei; Pu, Zenghui; Chen, Ling; Sun, Baoxia; Liu, Xi; Hamilton, Carol; Li, Lanjuan

doi:10.1097/ccm.0000000000001616

Cited by 136 publications

(142 citation statements)

References 33 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Specific antiviral treatment was initiated early in this H7N4 case (5 days after onset of disease), compared with the median time of H7N9 patients (7 days) [22]. High-dose corticosteroid therapy (>150 mg/d methylprednisolone or equivalent) was reported to significantly increase mortality and viral shedding time of H7N9 patients [26]. In this case, the dose implemented was low to moderate (20-80 mg/d).…”

Section: Discussionmentioning

confidence: 84%

Severe human infection with a novel avian-origin influenza A(H7N4) virus

Xiang

Cui

Chen³

et al. 2018

Science Bulletin

View full text Add to dashboard Cite

a b s t r a c tHuman infections with influenza H7 subtypes, such as H7N9, have raised concerns worldwide. Here, we report a human infection with a novel influenza A(H7N4) virus. A 68 years-old woman with cardiovascular and cholecystic comorbidities developed rapidly progressed pneumonia with influenza-like-illness as initial symptom, recovered after 23 days-hospitalization including 8 days in ICU. Laboratory indicators for liver and blood coagulation dysfunction were observed. Oseltamivir phosphate, glucocorticoids and antibiotics were jointly implemented, with nasal catheterization of oxygen inhalation for this patient. We obtained the medical records and collected serial respiratory and blood specimens from her. We collected throat, cloacal and/or feces samples of poultry and wild birds from the patient's backyard, neighborhood, local live poultry markets (LPMs) and the nearest lake. All close contacts of the patient were followed up and sampled with throat swabs and sera. Influenza viruses and other respiratory pathogens were tested by real-time RT-PCR, viral culturing and/or sequencing for human respiratory and bird samples. Micro-neutralizing assay was performed for sera. A novel reassortant wild bird-origin H7N4 virus is identified from the patient and her backyard poultry (chickens and ducks) by sequencing, which is distinct from previously-reported avian H7N4 and H7N9 viruses. At least four folds increase of neutralizing antibodies to H7N4 was detected in her convalescent sera. No samples from close contacts, wild birds or other poultry were tested positive for H7N4 by real-time RT-PCR.

show abstract

Section: Discussionmentioning

confidence: 84%

Severe human infection with a novel avian-origin influenza A(H7N4) virus

Xiang

Cui

Chen³

et al. 2018

Science Bulletin

View full text Add to dashboard Cite

show abstract

“…Various studies reported that GCs administration in patients with severe influenza pneumonia was associated with a higher rate of mortality [40][41][42][43][44]. A meta-analysis conducted with a total of 6548 patients with influenza pneumonia (H7N9 or H1N1), found the use of systemic GCs (methylprednisolone with different dose ranges, when reported) associated with higher mortality rate (risk ratio [RR] 1.75, 95% confidence interval [CI] 1.30-2.36, Z = 3.71, P = 0.0002), longer intensive care unit permanence and higher rate of secondary infection [44][45][46]. Only trials in recruiting status were included about the use of Hydroxychloroquine.…”

Section: Glucocorticoidsmentioning

confidence: 99%

The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

Perricone

Triggianese

Bartoloni

et al. 2020

Journal of Autoimmunity

128

131

View full text Add to dashboard Cite

“…In comparison to controls who did not receive systemic corticosteroids, high‐dose systemic corticosteroids (defined as >150 mg/day methylprednisolone equivalent) was associated with increased risks of 30‐day mortality (38.5% vs 7.7%, P = 0.021) and 60‐day mortality (50% vs 15.4%, P = 0.022) and longer viral shedding (15 vs 13 days, P = 0.039) among patients with influenza A(H7N9) viral pneumonia. There was no difference between low dose (25–150 mg/day methylprednisolone) and controls …”

Section: Disclosure Statementmentioning

confidence: 85%